The WHO has initiated a comprehensive gap analysis of the most needed medicines for children in view of its upcoming review of the Essential Medicines List for children (EMLc).
To date, the WHO Model EMLc has included 336 essential medicines, which patients should have immediate access to at all times and in all public health care facilities. Still, many medicines of major clinical importance are missing, or have not been readily tested, officially approved for use, or appropriately formulated for children, especially for the very young.
The Global Accelerator for Paediatric formulations (GAP-f) is a WHO-led network focused on achieving Universal Health Coverage by providing better medicines for children in need. Its mission is to prioritize, evaluate, develop and deliver high-quality medicines in optimal formulations for children. Currently, GAP-f is working on accelerating the development of paediatric formulations in the fields of HIV, tuberculosis and hepatitis C. In the near future it will extend the scope of its activities to other therapeutic areas covered by the EMLc, based on the review of the list and the identification of missing essential paediatric formulations.
To support the WHO review of the Essential Medicines List for children, we are gathering the opinion of experts and health care specialists on which paediatric formulations are missing. Your help would be fundamental.
We would be very grateful if you complete this survey, that should not take more than 20 minutes of your time. You can send your feedback only once, but you can edit your responses until the survey is closed on December 31st, 2020.
Please do not hesitate to share the link with other colleagues who you think may provide a knowledgeable opinion. We remain available to clarify any doubt you may have on the survey and will be happy to assist and receive your questions at the following email address: elisa.barbieri(at)pentafoundation.org